- Financial Times•7 hours ago
Sir, AstraZeneca has entered into an agreement with Pfizer to sell the development and commercialisation rights to its late-stage small molecule antibiotics business ("AstraZeneca in $1.6bn antibiotic ...
- Reuters•7 hours ago
The U.S. Securities and Exchange Commission detailed the settlement with the London-based drug company in an order instituting an administrative proceeding arising out of violations of provisions in the Foreign Corrupt Practices Act. AstraZeneca, which cooperated with the probe, neither admitted nor denied wrongdoing.
- 24/7 Wall St.•2 days ago
Major pharmaceuticals have been under fire in light of the recent Mylan EpiPen pricing fiasco, but now a key research firm is seeing one of these companies in a positive light.
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||4,890.00 x 20700|
|Ask||5,100.00 x 15300|
|Day's Range||4,962.00 - 5,109.63|
|52wk Range||3,680.00 - 5,505.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||28.58|
|Avg Vol (3m)||2,853,342|
|Dividend & Yield||N/A (N/A)|